0 CHECKOUT

VERTEX , Positive Investment Alert - HCV/HIV Co-Infection – An Untapped Opportunity!

  • ID: 1948434
  • October 2011
  • MP Advisors

Vertex (VRTX) next target is to capture the HCV/HIV co-infected patients and gain greater HCV market through shorter duration and dosing advantage to a niche pts population of IL28B CC Genotype. We expect most of the near term milestones related to Earnings, Rheumatoid Arthritis (RA), Cystic Fibrosis (CF), etc. programs to have a positive impact on the stock price. For more details, please read our report released on 25th October, 2011 on VRTX titled “HCV/HIV Co-Infection – An Untapped Opportunity!”

Note: Product cover images may vary from those shown

- Cystic Fibrosis
- HCV/HIV Co-Infection
- HCV Pipeline
- Incivek
- Interferon free HCV drug
- Vertex
- VX-509
- VX-770
- VX-809
- Victrelis

Note: Product cover images may vary from those shown

- Cystic Fibrosis
- HCV/HIV Co-Infection
- HCV Pipeline
- Incivek
- Interferon free HCV drug
- Vertex
- VX-509
- VX-770
- VX-809
- Victrelis

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: This company profile will be emailed to you. The company profile is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: This company profile will be emailed to you. The company profile is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: This company profile will be emailed to you. The company profile is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS

Our Clients

  • Pfizer, Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S